Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KUR 115

Drug Profile

KUR 115

Alternative Names: KUR115

Latest Information Update: 28 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kuros Biosurgery
  • Developer Kuros Biosciences
  • Class Blood proteins; Peptide hormones; Serine endopeptidases
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bone disorders

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Bone-disorders in USA (Implant)
  • 15 Oct 2015 Pharmacodynamics and adverse events data from a preclinical trial in Spinal fusion released by Kuros Biosurgery
  • 08 Sep 2015 Phase-I clinical trials in Spinal fusion in USA (unspecified route) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top